NO993670L - Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS - Google Patents

Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS

Info

Publication number
NO993670L
NO993670L NO993670A NO993670A NO993670L NO 993670 L NO993670 L NO 993670L NO 993670 A NO993670 A NO 993670A NO 993670 A NO993670 A NO 993670A NO 993670 L NO993670 L NO 993670L
Authority
NO
Norway
Prior art keywords
aids
drugs
inhibitors
treatment
reverse transcriptase
Prior art date
Application number
NO993670A
Other languages
Norwegian (no)
Other versions
NO993670D0 (en
Inventor
Arnold Paessens
Martin Blunck
Guenter Riess
Joerg-Peter Kleim
Manfred Roesner
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO993670D0 publication Critical patent/NO993670D0/en
Publication of NO993670L publication Critical patent/NO993670L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse vedrører anvendelse av quinoksaliner i en trippelkombina- sjon med proteaseinhibitorer og reverstranskriptaseinhibitorer som medikamenter for behandling av AIDS- og/eller HIV-infeksjoner.The present invention relates to the use of quinoxalines in a triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS and / or HIV infections.

NO993670A 1997-01-29 1999-07-28 Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS NO993670L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19703131A DE19703131A1 (en) 1997-01-29 1997-01-29 Use of quinoxaline in a combination of three with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of AIDS and / or HIV infections
PCT/EP1998/000197 WO1998032442A1 (en) 1997-01-29 1998-01-15 Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as medicines for treating aids

Publications (2)

Publication Number Publication Date
NO993670D0 NO993670D0 (en) 1999-07-28
NO993670L true NO993670L (en) 1999-09-10

Family

ID=7818634

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993670A NO993670L (en) 1997-01-29 1999-07-28 Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS

Country Status (16)

Country Link
EP (1) EP0977570A1 (en)
JP (1) JP2001511124A (en)
KR (1) KR20000070543A (en)
CN (1) CN1251525A (en)
AR (1) AR011094A1 (en)
AU (1) AU6094098A (en)
BR (1) BR9807523A (en)
CA (1) CA2278773A1 (en)
DE (1) DE19703131A1 (en)
ID (1) ID22414A (en)
IL (1) IL130877A0 (en)
NO (1) NO993670L (en)
PL (1) PL334770A1 (en)
SK (1) SK99899A3 (en)
WO (1) WO1998032442A1 (en)
ZA (1) ZA98679B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
GB9821000D0 (en) * 1998-09-28 1998-11-18 Glaxo Group Ltd Antiviral combinations
GB9911887D0 (en) * 1999-05-21 1999-07-21 Glaxo Group Ltd Methods and medicaments for post exposure prophylaxis of an hiv infection
SE9902987D0 (en) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
CO5300399A1 (en) 2000-02-25 2003-07-31 Astrazeneca Ab HETEROCICLIOCS CONTAINING NITROGEN, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US7005439B2 (en) 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
AR035230A1 (en) 2001-03-19 2004-05-05 Astrazeneca Ab BENCIMIDAZOL COMPOUNDS, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION, AND USES OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101038D0 (en) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
SE0103818D0 (en) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0301369D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
EP1962841A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl urea for treating virus infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0509398B1 (en) * 1991-04-15 2001-09-19 Aventis Pharma Deutschland GmbH Quinoxalines, process for their preparation and their use
DE4342024A1 (en) * 1993-12-09 1995-06-14 Hoechst Ag Combination preparations containing a quinoxaline and a nucleoside
DE19506742A1 (en) * 1995-02-27 1996-08-29 Bayer Ag Use of quinoxalines in combination with protease inhibitors as medicaments for the treatment of AIDS and / or HIV infections

Also Published As

Publication number Publication date
AU6094098A (en) 1998-08-18
JP2001511124A (en) 2001-08-07
AR011094A1 (en) 2000-08-02
ID22414A (en) 1999-10-14
BR9807523A (en) 2000-03-21
NO993670D0 (en) 1999-07-28
CN1251525A (en) 2000-04-26
ZA98679B (en) 1998-08-05
KR20000070543A (en) 2000-11-25
PL334770A1 (en) 2000-03-13
EP0977570A1 (en) 2000-02-09
SK99899A3 (en) 2000-03-13
WO1998032442A1 (en) 1998-07-30
CA2278773A1 (en) 1998-07-30
DE19703131A1 (en) 1998-07-30
IL130877A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
NO993670L (en) Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS
BR0309557A (en) Non-Nucleoside Reverse Transcriptase Inhibitors
FI955315A0 (en) Inhibitors of HIV protease, useful in the treatment of AIDS
TR200002759T2 (en) Cabergoline use in the treatment of leg numbness syndrome.
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
CY1112560T1 (en) Pulmonary transport of aminoglycosides
NO20014303D0 (en) JAK-3 inhibitors for the treatment of allergic disorders
ME00578A (en) Use of gastrointestinal lipase inhibitors
NO960775L (en) Use of quinoxalins in combination with protease inhibitors as a drug for the treatment of AIDS and / or HIV infections
ATE277943T1 (en) TRYPSIN INHIBITORS
HUP9901642A2 (en) Remedies or preventives for aids
TR199700735T1 (en) Concomitant therapy for HIV infection with the use of the reverse transcriptase inhibitor 3T and the HIV protease inhibitor indinavir, optionally with azt, DD1 or DDC.
FI951078A (en) Inhibition of retroviral infection
ATE148105T1 (en) SUCCINOYLAMINOHYDROXYETHYLAMINOSULFAMIC ACID OF VATES AND THEIR USE AS RETROVIRAL PROTEASE INHIBITORS
ES2195905T3 (en) TIOFEN-ETIL-TIOUREA COMPOUNDS AND ITS USE IN THE TREATMENT OF AIDS.
NO20040561L (en) Treatment of lipodystrophy
AU2002231643A1 (en) Light arrangement comprising at least two edge rails lying opposite each other
DK1032407T3 (en) Use of putamen ovi
ECSP961660A (en) COMBINED THERAPY FOR HIV INFECTION

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application